Seattle Children’s launches BrainChild Bio to commercialize novel CAR T-cell therapies for pediatric brain tumors, initially targeting DIPG

Seattle Children’s has launched BrainChild Bio, an independently managed company funded initially by Seattle Children’s, to commercialize novel CAR T-cell therapies for pediatric central nervous system tumors and advance ongoing clinical trials focusing first on diffuse intrinsic pontine glioma (DIPG) and other pediatric brain tumors.

MMichael Jensen BBrainChild Bio, Inc. SSeattle Children's Hospital